semaglutide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42608656
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
- 저자
- Malek Ayoub, Tsubasa Tsutsumi, Mary E Rinella
- 저널
- Alimentary pharmacology & therapeutics
- 공개일
- 2026 Aug 17
- 연구 유형
- 기타
- DOI
- 10.1111/apt.70921
문헌 요약
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading indication for liver transplantation, and fibrosis stage most strongly predicts clinical outcomes. Pharmacologic treatment is now available with resmetirom and semaglutide holding conditional approval. To describe the therapeutic landscape for MASH with a focus on anti-fibrotic impact. N…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.